Adamas Pharmaceuticals Inc (NASDAQ:ADMS) rose 5.3% during trading on Tuesday . The company traded as high as $34.14 and last traded at $33.87. Approximately 612,876 shares changed hands during trading, a decline of 15% from the average daily volume of 724,513 shares. The stock had previously closed at $32.15.

ADMS has been the topic of a number of research analyst reports. Mizuho reissued a “buy” rating and set a $48.00 price objective (up previously from $26.00) on shares of Adamas Pharmaceuticals in a report on Wednesday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Adamas Pharmaceuticals in a research note on Sunday, September 17th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 20th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Finally, Noble Financial reaffirmed a “buy” rating and issued a $33.00 target price on shares of Adamas Pharmaceuticals in a research note on Friday, September 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Adamas Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $44.86.

The company has a market cap of $793.82, a P/E ratio of -10.38 and a beta of 1.13. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.03). The company’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.66) EPS. equities analysts forecast that Adamas Pharmaceuticals Inc will post -3.84 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. boosted its stake in Adamas Pharmaceuticals by 2.6% during the 2nd quarter. Alliancebernstein L.P. now owns 717,617 shares of the specialty pharmaceutical company’s stock worth $12,551,000 after acquiring an additional 17,972 shares during the last quarter. Granite Point Capital Management L.P. boosted its stake in Adamas Pharmaceuticals by 11.9% during the 2nd quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock worth $4,609,000 after acquiring an additional 28,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in Adamas Pharmaceuticals by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock worth $13,034,000 after acquiring an additional 28,818 shares during the last quarter. Citadel Advisors LLC bought a new position in Adamas Pharmaceuticals during the 2nd quarter worth approximately $606,000. Finally, Virtu KCG Holdings LLC bought a new position in Adamas Pharmaceuticals during the 2nd quarter worth approximately $184,000. 79.40% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals (ADMS) Stock Price Up 5.3%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/11/adamas-pharmaceuticals-adms-stock-price-up-5-3.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.